💡Are PD biomarkers impacting on the RP2D for Phase 1 IO trials? Will blood based biomarkers overcome tissue biomarkers? Should paired biopsies be included in every single phase 1 IO protocol? Take a look at @salawuta abstract at #ASCO21 https://t.co/V5H3uKiPjy